ELTX

Elicio Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-12

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.56USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-12

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-K for 2025, filed 2026-03-12
The filing itself
8.87Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
- 10-K for 2025, filed 2026-03-12
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.32 against 0.71 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Sales

31.5

2012-12-31 to 2022-12-31100 at the start31.5

Sales: 100.00 on 2012-12-31 to 31.53 on 2022-12-31, down 68%.

Profit

-12,877

2012-12-31 to 2025-12-31100 at the start-12,877

Profit: 100.00 on 2012-12-31 to -12876.87 on 2025-12-31, down 12977%.

Shares in issue

1,037

2020-12-31 to 2025-12-31100 at the start1,037

Shares in issue: 100.00 on 2020-12-31 to 1037.30 on 2025-12-31, up 937%.

Sales is at 32, Profit is at -12877, Shares in issue is at 1037, against 100 in 2012.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-12

Sales, where the first year is 10032
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself
Profit, where the first year is 100-12,877
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself
Shares in issue, where the first year is 1001,037
Source
filed
Statement
income
Fiscal year
2025
Accession
0001601485-26-000027
Reported in
USD
The filing itself